Enrollment complete in orismilast psoriasis study

Union Therapeutics has completed patient enrollment in a phase 2b trial of orismilast MR tablets for the treatment of psoriasis, the company announced in a press release.

Orismilast MR tablet, a PDE4 inhibitor, is in development for the treatment of psoriasis, atopic dermatitis and hidradenitis suppurativa.

The randomized, double-blind, placebo-controlled, parallel-group, dose-ranging, phase 2b IASOS study includes 200 patients randomly assigned to receive one of three active orismilast doses or placebo twice daily.

“We are delighted to reach this significant milestone for orismilast modified release as we work diligently to provide a potential best-in-class treatment for patients with psoriasis,” Kim Domela Kjøller, MD, CEO of Union, said in the release. “The fast speed of patient enrollment in the IASOS study is outstanding, underpinning the medical need for new improved oral treatments and importantly brings it one step closer to patients with psoriasis.”

Topline data is expected in the first half of 2023.